A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer

Cancer Research

Volumn 68, Issue 3, 2008, Pages 645-649

  Laxman, Bharathi ^a   Morris, David S ^a   Yu, Jianjun ^a   Siddiqui, Javed ^a   Cao, Jie ^a   Mehra, Rohit ^a   Lonigro, Robert J ^a   Tsodikov, Alex ^a,b   Wei, John T ^a   Tomlins, Scott A ^a   Chinnaiyan, Arul M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; BIOLOGICAL MARKER; GOLPH 2 PROTEIN; INTESTINAL TREFOIL FACTOR; INTESTINAL TREFOIL FACTOR 3; PROSTATE SPECIFIC ANTIGEN; PROTEIN SUBUNIT; SERINE PROTEINASE; TRANSCRIPTION FACTOR ERG; TRANSMEMBRANE PROTEASE SERINE 2; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE MARKER; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; UNIVARIATE ANALYSIS; URINALYSIS;

ANTIGENS, NEOPLASM; CARRIER PROTEINS; DNA, COMPLEMENTARY; DNA-BINDING PROTEINS; HUMANS; MALE; MEMBRANE PROTEINS; ONCOGENE PROTEINS, FUSION; PEPTIDES; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; RNA, NEOPLASM; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 38849169937     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-3224     Document Type: Article

References (30)

1. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992;147:841-5.
2. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
3. Brawley OW, Knopf K, Merrill R. The epidemiology of prostate cancer part I: descriptive epidemiology. Semin Urol Oncol 1998;16:187-92.
4. Catalona WJ, Hudson MA, Scardino PT, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994;152:2037-42.
5. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
6. Rubin MA, Zhou M, Dhanasekaran SM, et al. α-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002;287:1662-70.
7. de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62:2695-8.
8. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
9. van Gils MP, Hessels D, van Hooij O, et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 2007;13:939-43.
10. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
11. Schmidt U, Fuessel S, Koch R, et al. Quantitative multi-gene expression profiling of primary prostate cancer. Prostate 2006;66:1521-34.
12. Laxman B, Tomlins SA, Mehra R, et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006;8:885-8.
13. Tomlins SA, Mehra R, Rhodes DR, et al. Whole transcriptome amplification for gene expression profiling and development of molecular archives. Neoplasia 2006;8:153-62.
14. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
15. Kumar-Sinha C, Shah RB, Laxman B, et al. Elevated α-methylacyl-CoA racemase enzymatic activity in prostate cancer. Am J Pathol 2004;164:787-93.
16. Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 2001;158:419-29.
17. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007;31:882-8.
18. Venables WN, Ripley BD. Modern applied statistics with S. 4th ed. New York: Springer; 2002.
19. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
20. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
21. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71.
22. Kattan MW, Stapleton AM, Wheeler TM, Scardino PT. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997;79:528-37.
23. Faith DA, Isaacs WB, Morgan JD, et al. Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate 2004;61:215-27.
24. Garraway IP, Seligson D, Said J, Horvath S, Reiter RE. Trefoil factor 3 is overexpressed in human prostate cancer. Prostate 2004;61:209-14.
25. Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15;discussion 6.
26. Fradet Y, Saad F, Aprikian A, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004;64:311-5; discussion 315-6.
27. Groskopf J, Aubin SM, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52:1089-95.
28. Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007;69:532-5.
29. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
30. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007;13:5103-8.